ID   GTR1_HUMAN              Reviewed;         492 AA.
AC   P11166; A8K9S6; B2R620; D3DPX0; O75535; Q147X2;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 2.
DT   10-MAY-2017, entry version 208.
DE   RecName: Full=Solute carrier family 2, facilitated glucose transporter member 1;
DE   AltName: Full=Glucose transporter type 1, erythrocyte/brain;
DE            Short=GLUT-1;
DE   AltName: Full=HepG2 glucose transporter;
GN   Name=SLC2A1; Synonyms=GLUT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, GLYCOSYLATION AT
RP   ASN-45, LACK OF GLYCOSYLATION AT ASN-411, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=3839598; DOI=10.1126/science.3839598;
RA   Mueckler M., Caruso C., Baldwin S.A., Panico M., Blench I.,
RA   Morris H.R., Allard W.J., Lienhard G.E., Lodish H.F.;
RT   "Sequence and structure of a human glucose transporter.";
RL   Science 229:941-945(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-6.
RX   PubMed=2834252; DOI=10.2337/diab.37.5.657;
RA   Fukumoto H., Seino S., Imura H., Seino Y., Bell G.I.;
RT   "Characterization and expression of human HepG2/erythrocyte glucose-
RT   transporter gene.";
RL   Diabetes 37:657-661(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 150-492.
RC   TISSUE=Brain;
RA   Yu W., Gibbs R.A.;
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 294-423.
RC   TISSUE=Articular cartilage;
RA   Neama G., Richardson S., Bell S., Carter S., Mobasheri A.;
RT   "Molecular characterization and cloning of glucose transporters in
RT   human articular chondrocytes.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ILE-192; LEU-204
RP   AND PRO-205.
RX   PubMed=18245775; DOI=10.1074/jbc.M708896200;
RA   Mueckler M., Makepeace C.;
RT   "Transmembrane segment 6 of the Glut1 glucose transporter is an outer
RT   helix and contains amino acid side chains essential for transport
RT   activity.";
RL   J. Biol. Chem. 283:11550-11555(2008).
RN   [10]
RP   IDENTIFICATION IN A COMPLEX WITH ADD2 AND DMTN, INTERACTION WITH DMTN,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=18347014; DOI=10.1074/jbc.M707818200;
RA   Khan A.A., Hanada T., Mohseni M., Jeong J.J., Zeng L., Gaetani M.,
RA   Li D., Reed B.C., Speicher D.W., Chishti A.H.;
RT   "Dematin and adducin provide a novel link between the spectrin
RT   cytoskeleton and human erythrocyte membrane by directly interacting
RT   with glucose transporter-1.";
RL   J. Biol. Chem. 283:14600-14609(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF GLY-340.
RX   PubMed=19449892; DOI=10.1021/bi900521n;
RA   Mueckler M., Makepeace C.;
RT   "Model of the exofacial substrate-binding site and helical folding of
RT   the human Glut1 glucose transporter based on scanning mutagenesis.";
RL   Biochemistry 48:5934-5942(2009).
RN   [13]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-45.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-478, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-490, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [18]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, INTERACTION WITH STOM, AND
RP   SUBUNIT.
RX   PubMed=23219802; DOI=10.1016/j.bbamem.2012.11.030;
RA   Rungaldier S., Oberwagner W., Salzer U., Csaszar E., Prohaska R.;
RT   "Stomatin interacts with GLUT1/SLC2A1, band 3/SLC4A1, and aquaporin-1
RT   in human erythrocyte membrane domains.";
RL   Biochim. Biophys. Acta 1828:956-966(2013).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-465 AND SER-490, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   INTERACTION WITH SNX27.
RX   PubMed=23563491; DOI=10.1038/ncb2721;
RA   Steinberg F., Gallon M., Winfield M., Thomas E.C., Bell A.J.,
RA   Heesom K.J., Tavare J.M., Cullen P.J.;
RT   "A global analysis of SNX27-retromer assembly and cargo specificity
RT   reveals a function in glucose and metal ion transport.";
RL   Nat. Cell Biol. 15:461-471(2013).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-490, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF VARIANT GLUT1DS1 GLN-329 IN
RP   COMPLEX WITH NONYL-BETA-D-GLUCOSIDE, SUBCELLULAR LOCATION, TOPOLOGY,
RP   AND MUTAGENESIS OF ASN-45.
RX   PubMed=24847886; DOI=10.1038/nature13306;
RA   Deng D., Xu C., Sun P., Wu J., Yan C., Hu M., Yan N.;
RT   "Crystal structure of the human glucose transporter GLUT1.";
RL   Nature 510:121-125(2014).
RN   [23]
RP   VARIANT GLUT1DS1 ILE-310.
RX   PubMed=10227690; DOI=10.1023/A:1022544131826;
RA   Klepper J., Wang D., Fischbarg J., Vera J.C., Jarjour I.T.,
RA   O'Driscoll K.R., De Vivo D.C.;
RT   "Defective glucose transport across brain tissue barriers: a newly
RT   recognized neurological syndrome.";
RL   Neurochem. Res. 24:587-594(1999).
RN   [24]
RP   VARIANTS GLUT1DS1 PHE-66; LEU-126; LYS-146; GLU-256 AND TRP-333.
RX   PubMed=10980529;
RX   DOI=10.1002/1098-1004(200009)16:3<224::AID-HUMU5>3.3.CO;2-G;
RA   Wang D., Kranz-Eble P., De Vivo D.C.;
RT   "Mutational analysis of GLUT1 (SLC2A1) in Glut-1 deficiency
RT   syndrome.";
RL   Hum. Mutat. 16:224-231(2000).
RN   [25]
RP   ERRATUM.
RA   Wang D., Kranz-Eble P., De Vivo D.C.;
RL   Hum. Mutat. 16:527-527(2000).
RN   [26]
RP   VARIANT GLUT1DS1 HIS-126.
RX   PubMed=11603379; DOI=10.1002/ana.1222;
RA   Brockmann K., Wang D., Korenke C.G., von Moers A., Ho Y.-Y.,
RA   Pascual J.M., Kuang K., Yang H., Ma L., Kranz-Eble P., Fischbarg J.,
RA   Hanefeld F., De Vivo D.C.;
RT   "Autosomal dominant Glut-1 deficiency syndrome and familial
RT   epilepsy.";
RL   Ann. Neurol. 50:476-485(2001).
RN   [27]
RP   VARIANT GLUT1DS1 ASP-91.
RX   PubMed=11136715; DOI=10.1093/hmg/10.1.63;
RA   Klepper J., Willemsen M., Verrips A., Guertsen E., Herrmann R.,
RA   Kutzick C., Floercken A., Voit T.;
RT   "Autosomal dominant transmission of GLUT1 deficiency.";
RL   Hum. Mol. Genet. 10:63-68(2001).
RN   [28]
RP   VARIANTS GLUT1DS1 CYS-126; HIS-126; LYS-146; CYS-153 AND TRP-333.
RX   PubMed=12325075; DOI=10.1002/ana.10311;
RA   Pascual J.M., van Heertum R.L., Wang D., Engelstad K., De Vivo D.C.;
RT   "Imaging the metabolic footprint of Glut1 deficiency on the brain.";
RL   Ann. Neurol. 52:458-464(2002).
RN   [29]
RP   VARIANT GLUT1DS2 ILE-34.
RX   PubMed=14605501; DOI=10.1023/A:1025999914822;
RA   Overweg-Plandsoen W.C.G., Groener J.E.M., Wang D., Onkenhout W.,
RA   Brouwer O.F., Bakker H.D., De Vivo D.C.;
RT   "GLUT-1 deficiency without epilepsy -- an exceptional case.";
RL   J. Inherit. Metab. Dis. 26:559-563(2003).
RN   [30]
RP   VARIANTS GLUT1DS1 SER-34; HIS-126; SER-130; CYS-153; LEU-169 DEL;
RP   MET-295 AND TRP-333, AND CHARACTERIZATION OF VARIANTS GLUT1 DEFICIENCY
RP   SER-34; HIS-126; SER-130; CYS-153; LEU-169 DEL; MET-295 AND TRP-333.
RX   PubMed=15622525; DOI=10.1002/ana.20331;
RA   Wang D., Pascual J.M., Yang H., Engelstad K., Jhung S., Sun R.P.,
RA   De Vivo D.C.;
RT   "Glut-1 deficiency syndrome: clinical, genetic, and therapeutic
RT   aspects.";
RL   Ann. Neurol. 57:111-118(2005).
RN   [31]
RP   VARIANTS GLUT1DS2 THR-275; 282-GLN--SER-285 DEL AND SER-314.
RX   PubMed=18451999; DOI=10.1172/JCI34438;
RA   Weber Y.G., Storch A., Wuttke T.V., Brockmann K., Kempfle J.,
RA   Maljevic S., Margari L., Kamm C., Schneider S.A., Huber S.M.,
RA   Pekrun A., Roebling R., Seebohm G., Koka S., Lang C., Kraft E.,
RA   Blazevic D., Salvo-Vargas A., Fauler M., Mottaghy F.M., Muenchau A.,
RA   Edwards M.J., Presicci A., Margari F., Gasser T., Lang F.,
RA   Bhatia K.P., Lehmann-Horn F., Lerche H.;
RT   "GLUT1 mutations are a cause of paroxysmal exertion-induced
RT   dyskinesias and induce hemolytic anemia by a cation leak.";
RL   J. Clin. Invest. 118:2157-2168(2008).
RN   [32]
RP   VARIANT EIG12 PRO-223, VARIANTS GLUT1DS2 CYS-126 AND LEU-324,
RP   CHARACTERIZATION OF VARIANT EIG12 PRO-223, AND CHARACTERIZATION OF
RP   VARIANTS GLUT1DS2 CYS-126 AND LEU-324.
RX   PubMed=19798636; DOI=10.1002/ana.21724;
RA   Suls A., Mullen S.A., Weber Y.G., Verhaert K., Ceulemans B.,
RA   Guerrini R., Wuttke T.V., Salvo-Vargas A., Deprez L., Claes L.R.,
RA   Jordanova A., Berkovic S.F., Lerche H., De Jonghe P., Scheffer I.E.;
RT   "Early-onset absence epilepsy caused by mutations in the glucose
RT   transporter GLUT1.";
RL   Ann. Neurol. 66:415-419(2009).
RN   [33]
RP   VARIANT GLUT1DS1 TYR-292 INS.
RX   PubMed=19901175; DOI=10.1001/archneurol.2009.236;
RA   Perez-Duenas B., Prior C., Ma Q., Fernandez-Alvarez E., Setoain X.,
RA   Artuch R., Pascual J.M.;
RT   "Childhood chorea with cerebral hypotrophy: a treatable GLUT1 energy
RT   failure syndrome.";
RL   Arch. Neurol. 66:1410-1414(2009).
RN   [34]
RP   VARIANTS GLUT1DS2 TRP-92 AND GLN-333.
RX   PubMed=19630075; DOI=10.1002/mds.22507;
RA   Schneider S.A., Paisan-Ruiz C., Garcia-Gorostiaga I., Quinn N.P.,
RA   Weber Y.G., Lerche H., Hardy J., Bhatia K.P.;
RT   "GLUT1 gene mutations cause sporadic paroxysmal exercise-induced
RT   dyskinesias.";
RL   Mov. Disord. 24:1684-1688(2009).
RN   [35]
RP   VARIANT GLUT1DS1 TRP-468.
RX   PubMed=20221955; DOI=10.1055/s-0030-1248264;
RA   Klepper J., Scheffer H., Elsaid M.F., Kamsteeg E.J., Leferink M.,
RA   Ben-Omran T.;
RT   "Autosomal recessive inheritance of GLUT1 deficiency syndrome.";
RL   Neuropediatrics 40:207-210(2009).
RN   [36]
RP   VARIANTS GLUT1DS1 TYR-34; VAL-96; SER-130; VAL-155; CYS-212; HIS-212;
RP   TRP-223; MET-295; GLN-329; GLN-333; ASP-382; ASP-405 AND LEU-485,
RP   VARIANTS GLUT1DS2 TRP-93 AND HIS-153, AND VARIANT LEU-303.
RX   PubMed=20129935; DOI=10.1093/brain/awp336;
RA   Leen W.G., Klepper J., Verbeek M.M., Leferink M., Hofste T.,
RA   van Engelen B.G., Wevers R.A., Arthur T., Bahi-Buisson N.,
RA   Ballhausen D., Bekhof J., van Bogaert P., Carrilho I., Chabrol B.,
RA   Champion M.P., Coldwell J., Clayton P., Donner E., Evangeliou A.,
RA   Ebinger F., Farrell K., Forsyth R.J., de Goede C.G., Gross S.,
RA   Grunewald S., Holthausen H., Jayawant S., Lachlan K., Laugel V.,
RA   Leppig K., Lim M.J., Mancini G., Marina A.D., Martorell L.,
RA   McMenamin J., Meuwissen M.E., Mundy H., Nilsson N.O., Panzer A.,
RA   Poll-The B.T., Rauscher C., Rouselle C.M., Sandvig I., Scheffner T.,
RA   Sheridan E., Simpson N., Sykora P., Tomlinson R., Trounce J., Webb D.,
RA   Weschke B., Scheffer H., Willemsen M.A.;
RT   "Glucose transporter-1 deficiency syndrome: the expanding clinical and
RT   genetic spectrum of a treatable disorder.";
RL   Brain 133:655-670(2010).
RN   [37]
RP   VARIANT GLUT1DS2 THR-317.
RX   PubMed=21204808; DOI=10.1111/j.1528-1167.2010.02726.x;
RA   Afawi Z., Suls A., Ekstein D., Kivity S., Neufeld M.Y., Oliver K.,
RA   De Jonghe P., Korczyn A.D., Berkovic S.F.;
RT   "Mild adolescent/adult onset epilepsy and paroxysmal exercise-induced
RT   dyskinesia due to GLUT1 deficiency.";
RL   Epilepsia 51:2466-2469(2010).
RN   [38]
RP   VARIANT GLUT1DS2 ILE-165.
RX   PubMed=20621801; DOI=10.1016/j.jns.2010.05.017;
RA   Urbizu A., Cuenca-Leon E., Raspall-Chaure M., Gratacos M., Conill J.,
RA   Redecillas S., Roig-Quilis M., Macaya A.;
RT   "Paroxysmal exercise-induced dyskinesia, writer's cramp, migraine with
RT   aura and absence epilepsy in twin brothers with a novel SLC2A1
RT   missense mutation.";
RL   J. Neurol. Sci. 295:110-113(2010).
RN   [39]
RP   VARIANTS GLUT1DS2 ILE-95; PRO-223; SER-314 AND LEU-324, AND VARIANTS
RP   GLUT1DS1 ASP-91 AND HIS-126.
RX   PubMed=20574033; DOI=10.1212/WNL.0b013e3181eb58b4;
RA   Mullen S.A., Suls A., De Jonghe P., Berkovic S.F., Scheffer I.E.;
RT   "Absence epilepsies with widely variable onset are a key feature of
RT   familial GLUT1 deficiency.";
RL   Neurology 75:432-440(2010).
RN   [40]
RP   INVOLVEMENT IN SDCHCN, VARIANTS SDCHCN ASP-286 AND ILE-435 DEL, AND
RP   CHARACTERIZATION OF VARIANTS SDCHCN ASP-286 AND ILE-435 DEL.
RX   PubMed=21791420; DOI=10.1182/blood-2010-12-326645;
RA   Flatt J.F., Guizouarn H., Burton N.M., Borgese F., Tomlinson R.J.,
RA   Forsyth R.J., Baldwin S.A., Levinson B.E., Quittet P.,
RA   Aguilar-Martinez P., Delaunay J., Stewart G.W., Bruce L.J.;
RT   "Stomatin-deficient cryohydrocytosis results from mutations in SLC2A1:
RT   a novel form of GLUT1 deficiency syndrome.";
RL   Blood 118:5267-5277(2011).
RN   [41]
RP   VARIANT GLUT1DS2 PRO-294.
RX   PubMed=20830593; DOI=10.1007/s00415-010-5702-5;
RA   Anheim M., Maillart E., Vuillaumier-Barrot S., Flamand-Rouviere C.,
RA   Pineau F., Ewenczyk C., Riant F., Apartis E., Roze E.;
RT   "Excellent response to acetazolamide in a case of paroxysmal
RT   dyskinesias due to GLUT1-deficiency.";
RL   J. Neurol. 258:316-317(2011).
RN   [42]
RP   VARIANTS DYT9 CYS-126 AND CYS-212.
RX   PubMed=21832227; DOI=10.1212/WNL.0b013e31822e0479;
RA   Weber Y.G., Kamm C., Suls A., Kempfle J., Kotschet K., Schule R.,
RA   Wuttke T.V., Maljevic S., Liebrich J., Gasser T., Ludolph A.C.,
RA   Van Paesschen W., Schols L., De Jonghe P., Auburger G., Lerche H.;
RT   "Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1
RT   defect.";
RL   Neurology 77:959-964(2011).
RN   [43]
RP   VARIANTS EIG12 HIS-51; MET-60; THR-77; ALA-149; SER-218; GLN-223;
RP   VAL-243; SER-411 AND TRP-458, AND CHARACTERIZATION OF VARIANTS EIG12
RP   MET-60; THR-77; SER-218; GLN-223; VAL-243; SER-411 AND TRP-458.
RX   PubMed=23280796; DOI=10.1002/ana.23702;
RA   Arsov T., Mullen S.A., Rogers S., Phillips A.M., Lawrence K.M.,
RA   Damiano J.A., Goldberg-Stern H., Afawi Z., Kivity S., Trager C.,
RA   Petrou S., Berkovic S.F., Scheffer I.E.;
RT   "Glucose transporter 1 deficiency in the idiopathic generalized
RT   epilepsies.";
RL   Ann. Neurol. 72:807-815(2012).
RN   [44]
RP   INVOLVEMENT IN SDCHCN, VARIANT SDCHCN ILE-435 DEL, AND
RP   CHARACTERIZATION OF VARIANT SDCHCN ILE-435 DEL.
RX   PubMed=22492876; DOI=10.1210/jc.2012-1399;
RA   Bawazir W.M., Gevers E.F., Flatt J.F., Ang A.L., Jacobs B., Oren C.,
RA   Grunewald S., Dattani M., Bruce L.J., Stewart G.W.;
RT   "An infant with pseudohyperkalemia, hemolysis, and seizures: cation-
RT   leaky GLUT1-deficiency syndrome due to a SLC2A1 mutation.";
RL   J. Clin. Endocrinol. Metab. 97:E987-E993(2012).
RN   [45]
RP   VARIANT EIG12 CYS-232, AND CHARACTERIZATION OF VARIANT EIG12 CYS-232.
RX   PubMed=22282645; DOI=10.1212/WNL.0b013e318247ff54;
RA   Striano P., Weber Y.G., Toliat M.R., Schubert J., Leu C., Chaimana R.,
RA   Baulac S., Guerrero R., LeGuern E., Lehesjoki A.E., Polvi A.,
RA   Robbiano A., Serratosa J.M., Guerrini R., Nurnberg P., Sander T.,
RA   Zara F., Lerche H., Marini C.;
RT   "GLUT1 mutations are a rare cause of familial idiopathic generalized
RT   epilepsy.";
RL   Neurology 78:557-562(2012).
CC   -!- FUNCTION: Facilitative glucose transporter. This isoform may be
CC       responsible for constitutive or basal glucose uptake. Has a very
CC       broad substrate specificity; can transport a wide range of aldoses
CC       including both pentoses and hexoses. {ECO:0000269|PubMed:18245775,
CC       ECO:0000269|PubMed:19449892}.
CC   -!- SUBUNIT: Interacts with GIPC (via PDZ domain) (By similarity).
CC       Found in a complex with ADD2, DMTN and SLC2A1. Interacts (via C-
CC       terminus cytoplasmic region) with DMTN isoform 2
CC       (PubMed:18347014). Interacts with SNX27; the interaction is
CC       required when endocytosed to prevent degradation in lysosomes and
CC       promote recycling to the plasma membrane (PubMed:23563491).
CC       Interacts with STOM (PubMed:23219802). Interacts with SGTA (via
CC       Gln-rich region) (By similarity). {ECO:0000250|UniProtKB:P11167,
CC       ECO:0000269|PubMed:18347014, ECO:0000269|PubMed:23219802,
CC       ECO:0000269|PubMed:23563491}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-717153, EBI-717153;
CC       O43889-2:CREB3; NbExp=3; IntAct=EBI-717153, EBI-625022;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Melanosome. Note=Localizes primarily at the cell surface.
CC       Identified by mass spectrometry in melanosome fractions from stage
CC       I to stage IV.
CC   -!- TISSUE SPECIFICITY: Detected in erythrocytes (at protein level).
CC       Expressed at variable levels in many human tissues.
CC       {ECO:0000269|PubMed:23219802}.
CC   -!- DISEASE: GLUT1 deficiency syndrome 1 (GLUT1DS1) [MIM:606777]: A
CC       neurologic disorder showing wide phenotypic variability. The most
CC       severe 'classic' phenotype comprises infantile-onset epileptic
CC       encephalopathy associated with delayed development, acquired
CC       microcephaly, motor incoordination, and spasticity. Onset of
CC       seizures, usually characterized by apneic episodes, staring
CC       spells, and episodic eye movements, occurs within the first 4
CC       months of life. Other paroxysmal findings include intermittent
CC       ataxia, confusion, lethargy, sleep disturbance, and headache.
CC       Varying degrees of cognitive impairment can occur, ranging from
CC       learning disabilities to severe mental retardation.
CC       {ECO:0000269|PubMed:10227690, ECO:0000269|PubMed:10980529,
CC       ECO:0000269|PubMed:11136715, ECO:0000269|PubMed:11603379,
CC       ECO:0000269|PubMed:12325075, ECO:0000269|PubMed:15622525,
CC       ECO:0000269|PubMed:19901175, ECO:0000269|PubMed:20129935,
CC       ECO:0000269|PubMed:20221955, ECO:0000269|PubMed:20574033,
CC       ECO:0000269|PubMed:24847886}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: GLUT1 deficiency syndrome 2 (GLUT1DS2) [MIM:612126]: A
CC       clinically variable disorder characterized primarily by onset in
CC       childhood of paroxysmal exercise-induced dyskinesia. The
CC       dyskinesia involves transient abnormal involuntary movements, such
CC       as dystonia and choreoathetosis, induced by exercise or exertion,
CC       and affecting the exercised limbs. Some patients may also have
CC       epilepsy, most commonly childhood absence epilepsy. Mild mental
CC       retardation may also occur. In some patients involuntary exertion-
CC       induced dystonic, choreoathetotic, and ballistic movements may be
CC       associated with macrocytic hemolytic anemia.
CC       {ECO:0000269|PubMed:14605501, ECO:0000269|PubMed:18451999,
CC       ECO:0000269|PubMed:19630075, ECO:0000269|PubMed:19798636,
CC       ECO:0000269|PubMed:20129935, ECO:0000269|PubMed:20574033,
CC       ECO:0000269|PubMed:20621801, ECO:0000269|PubMed:20830593,
CC       ECO:0000269|PubMed:21204808}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Epilepsy, idiopathic generalized 12 (EIG12) [MIM:614847]:
CC       A disorder characterized by recurring generalized seizures in the
CC       absence of detectable brain lesions and/or metabolic
CC       abnormalities. Generalized seizures arise diffusely and
CC       simultaneously from both hemispheres of the brain. Seizure types
CC       include juvenile myoclonic seizures, absence seizures, and
CC       generalized tonic-clonic seizures. In some EIG12 patients seizures
CC       may remit with age. {ECO:0000269|PubMed:19798636,
CC       ECO:0000269|PubMed:22282645, ECO:0000269|PubMed:23280796}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Dystonia 9 (DYT9) [MIM:601042]: An autosomal dominant
CC       neurologic disorder characterized by childhood onset of paroxysmal
CC       choreoathetosis and progressive spastic paraplegia. Most patients
CC       show some degree of cognitive impairment. Other variable features
CC       may include seizures, migraine headaches, and ataxia.
CC       {ECO:0000269|PubMed:21832227}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Stomatin-deficient cryohydrocytosis with neurologic
CC       defects (SDCHCN) [MIM:608885]: A rare form of stomatocytosis
CC       characterized by episodic hemolytic anemia, cold-induced red cells
CC       cation leak, erratic hyperkalemia, neonatal hyperbilirubinemia,
CC       hepatosplenomegaly, cataracts, seizures, mental retardation, and
CC       movement disorder. {ECO:0000269|PubMed:21791420,
CC       ECO:0000269|PubMed:22492876}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the major facilitator superfamily. Sugar
CC       transporter (TC 2.A.1.1) family. Glucose transporter subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=GLUT1 entry;
CC       URL="https://en.wikipedia.org/wiki/GLUT1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; K03195; AAA52571.1; -; mRNA.
DR   EMBL; AK292791; BAF85480.1; -; mRNA.
DR   EMBL; AK312403; BAG35317.1; -; mRNA.
DR   EMBL; CH471059; EAX07124.1; -; Genomic_DNA.
DR   EMBL; BC118590; AAI18591.1; -; mRNA.
DR   EMBL; M20653; AAB61084.1; -; Genomic_DNA.
DR   EMBL; AF070544; AAC28635.1; -; mRNA.
DR   EMBL; AY034633; AAK56795.1; -; mRNA.
DR   CCDS; CCDS477.1; -.
DR   PIR; A27217; A27217.
DR   RefSeq; NP_006507.2; NM_006516.2.
DR   UniGene; Hs.473721; -.
DR   PDB; 1SUK; Model; -; A=1-492.
DR   PDB; 4PYP; X-ray; 3.17 A; A=1-492.
DR   PDB; 5EQG; X-ray; 2.90 A; A=1-492.
DR   PDB; 5EQH; X-ray; 2.99 A; A=1-492.
DR   PDB; 5EQI; X-ray; 3.00 A; A=1-492.
DR   PDBsum; 1SUK; -.
DR   PDBsum; 4PYP; -.
DR   PDBsum; 5EQG; -.
DR   PDBsum; 5EQH; -.
DR   PDBsum; 5EQI; -.
DR   ProteinModelPortal; P11166; -.
DR   SMR; P11166; -.
DR   BioGrid; 112404; 25.
DR   DIP; DIP-23N; -.
DR   IntAct; P11166; 26.
DR   MINT; MINT-1386229; -.
DR   STRING; 9606.ENSP00000416293; -.
DR   BindingDB; P11166; -.
DR   ChEMBL; CHEMBL2535; -.
DR   DrugBank; DB08831; 2-deoxyglucose.
DR   DrugBank; DB08830; Dehydroascorbic Acid.
DR   DrugBank; DB00292; Etomidate.
DR   GuidetoPHARMACOLOGY; 875; -.
DR   TCDB; 2.A.1.1.28; the major facilitator superfamily (mfs).
DR   iPTMnet; P11166; -.
DR   PhosphoSitePlus; P11166; -.
DR   SwissPalm; P11166; -.
DR   UniCarbKB; P11166; -.
DR   BioMuta; SLC2A1; -.
DR   DMDM; 115502394; -.
DR   EPD; P11166; -.
DR   MaxQB; P11166; -.
DR   PaxDb; P11166; -.
DR   PeptideAtlas; P11166; -.
DR   PRIDE; P11166; -.
DR   Ensembl; ENST00000426263; ENSP00000416293; ENSG00000117394.
DR   GeneID; 6513; -.
DR   KEGG; hsa:6513; -.
DR   UCSC; uc001cik.3; human.
DR   CTD; 6513; -.
DR   DisGeNET; 6513; -.
DR   GeneCards; SLC2A1; -.
DR   GeneReviews; SLC2A1; -.
DR   HGNC; HGNC:11005; SLC2A1.
DR   HPA; CAB002759; -.
DR   HPA; HPA031345; -.
DR   HPA; HPA058494; -.
DR   MalaCards; SLC2A1; -.
DR   MIM; 138140; gene.
DR   MIM; 601042; phenotype.
DR   MIM; 606777; phenotype.
DR   MIM; 608885; phenotype.
DR   MIM; 612126; phenotype.
DR   MIM; 614847; phenotype.
DR   neXtProt; NX_P11166; -.
DR   OpenTargets; ENSG00000117394; -.
DR   Orphanet; 64280; Childhood absence epilepsy.
DR   Orphanet; 71277; Encephalopathy due to GLUT1 deficiency.
DR   Orphanet; 168577; Hereditary cryohydrocytosis with reduced stomatin.
DR   Orphanet; 53583; Paroxysmal dystonic choreathetosis with episodic ataxia and spasticity.
DR   Orphanet; 98811; Paroxysmal exertion-induced dyskinesia.
DR   PharmGKB; PA35875; -.
DR   eggNOG; KOG0569; Eukaryota.
DR   eggNOG; COG0477; LUCA.
DR   GeneTree; ENSGT00760000119022; -.
DR   HOVERGEN; HBG014816; -.
DR   InParanoid; P11166; -.
DR   KO; K07299; -.
DR   OMA; MLMMNLL; -.
DR   OrthoDB; EOG091G0A9K; -.
DR   PhylomeDB; P11166; -.
DR   TreeFam; TF313762; -.
DR   Reactome; R-HSA-196836; Vitamin C (ascorbate) metabolism.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   Reactome; R-HSA-428790; Facilitative Na+-independent glucose transporters.
DR   Reactome; R-HSA-5653890; Lactose synthesis.
DR   Reactome; R-HSA-70153; Glucose transport.
DR   SIGNOR; P11166; -.
DR   ChiTaRS; SLC2A1; human.
DR   GeneWiki; GLUT1; -.
DR   GenomeRNAi; 6513; -.
DR   PRO; PR:P11166; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000117394; -.
DR   CleanEx; HS_SLC2A1; -.
DR   ExpressionAtlas; P11166; baseline and differential.
DR   Genevisible; P11166; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0072562; C:blood microparticle; IDA:UniProtKB.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0030864; C:cortical actin cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0001939; C:female pronucleus; IEA:Ensembl.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0030496; C:midbody; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0055056; F:D-glucose transmembrane transporter activity; IMP:UniProtKB.
DR   GO; GO:0033300; F:dehydroascorbic acid transporter activity; EXP:Reactome.
DR   GO; GO:0005355; F:glucose transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; IEA:Ensembl.
DR   GO; GO:0043621; F:protein self-association; IDA:UniProtKB.
DR   GO; GO:0042910; F:xenobiotic transporter activity; IEA:Ensembl.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IEA:Ensembl.
DR   GO; GO:1904659; P:glucose transmembrane transport; IMP:UniProtKB.
DR   GO; GO:0015758; P:glucose transport; IDA:UniProtKB.
DR   GO; GO:0019852; P:L-ascorbic acid metabolic process; TAS:Reactome.
DR   GO; GO:0005989; P:lactose biosynthetic process; TAS:Reactome.
DR   GO; GO:0006461; P:protein complex assembly; IDA:UniProtKB.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0006970; P:response to osmotic stress; IEA:Ensembl.
DR   CDD; cd06174; MFS; 1.
DR   InterPro; IPR002439; Glu_transpt_1.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR005828; MFS_sugar_transport-like.
DR   InterPro; IPR003663; Sugar/inositol_transpt.
DR   InterPro; IPR005829; Sugar_transporter_CS.
DR   Pfam; PF00083; Sugar_tr; 1.
DR   PRINTS; PR01190; GLUCTRSPORT1.
DR   PRINTS; PR00171; SUGRTRNSPORT.
DR   SUPFAM; SSF103473; SSF103473; 2.
DR   TIGRFAMs; TIGR00879; SP; 1.
DR   PROSITE; PS50850; MFS; 1.
DR   PROSITE; PS00216; SUGAR_TRANSPORT_1; 1.
DR   PROSITE; PS00217; SUGAR_TRANSPORT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cataract; Cell membrane; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Dystonia; Epilepsy;
KW   Glycoprotein; Hereditary hemolytic anemia; Membrane;
KW   Mental retardation; Phosphoprotein; Reference proteome;
KW   Sugar transport; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1    492       Solute carrier family 2, facilitated
FT                                glucose transporter member 1.
FT                                /FTId=PRO_0000050338.
FT   TOPO_DOM      1     11       Cytoplasmic.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM     12     33       Helical; Name=1.
FT   TOPO_DOM     34     66       Extracellular.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM     67     87       Helical; Name=2.
FT   TOPO_DOM     88     90       Cytoplasmic.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM     91    112       Helical; Name=3.
FT   TOPO_DOM    113    120       Extracellular.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM    121    144       Helical; Name=4.
FT   TOPO_DOM    145    155       Cytoplasmic.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM    156    176       Helical; Name=5.
FT   TOPO_DOM    177    185       Extracellular.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM    186    206       Helical; Name=6.
FT   TOPO_DOM    207    271       Cytoplasmic.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM    272    293       Helical; Name=7.
FT   TOPO_DOM    294    306       Extracellular.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM    307    328       Helical; Name=8.
FT   TOPO_DOM    329    334       Cytoplasmic.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM    335    355       Helical; Name=9.
FT   TOPO_DOM    356    365       Extracellular.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM    366    388       Helical; Name=10.
FT   TOPO_DOM    389    401       Cytoplasmic.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM    402    422       Helical; Name=11.
FT   TOPO_DOM    423    429       Extracellular.
FT                                {ECO:0000269|PubMed:24847886}.
FT   TRANSMEM    430    450       Helical; Name=12.
FT   TOPO_DOM    451    492       Cytoplasmic.
FT                                {ECO:0000269|PubMed:24847886}.
FT   REGION      282    288       Monosaccharide binding.
FT   BINDING     317    317       Monosaccharide.
FT   BINDING     388    388       Monosaccharide.
FT   SITE        411    411       Not glycosylated.
FT                                {ECO:0000269|PubMed:3839598}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES     465    465       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     478    478       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     490    490       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   CARBOHYD     45     45       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19349973,
FT                                ECO:0000269|PubMed:3839598}.
FT   VARIANT      34     34       N -> I (in GLUT1DS2; dbSNP:rs80359812).
FT                                {ECO:0000269|PubMed:14605501}.
FT                                /FTId=VAR_054755.
FT   VARIANT      34     34       N -> S (in GLUT1DS1; 55% of wild-type
FT                                glucose uptake activity).
FT                                {ECO:0000269|PubMed:15622525}.
FT                                /FTId=VAR_054756.
FT   VARIANT      34     34       N -> Y (in GLUT1DS1).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065206.
FT   VARIANT      51     51       R -> H (in EIG12; unknown pathological
FT                                significance; dbSNP:rs201815571).
FT                                {ECO:0000269|PubMed:23280796}.
FT                                /FTId=VAR_076226.
FT   VARIANT      60     60       T -> M (in EIG12; unknown pathological
FT                                significance; decreased glucose
FT                                transport; dbSNP:rs142986731).
FT                                {ECO:0000269|PubMed:23280796}.
FT                                /FTId=VAR_076227.
FT   VARIANT      66     66       S -> F (in GLUT1DS1; dbSNP:rs80359813).
FT                                {ECO:0000269|PubMed:10980529}.
FT                                /FTId=VAR_013283.
FT   VARIANT      77     77       M -> T (in EIG12; decreased glucose
FT                                transport).
FT                                {ECO:0000269|PubMed:23280796}.
FT                                /FTId=VAR_076228.
FT   VARIANT      91     91       G -> D (in GLUT1DS1; significantly
FT                                decreases the transport of 3-O-methyl-D-
FT                                glucose; dbSNP:rs80359814).
FT                                {ECO:0000269|PubMed:11136715,
FT                                ECO:0000269|PubMed:20574033}.
FT                                /FTId=VAR_013182.
FT   VARIANT      92     92       R -> W (in GLUT1DS2; dbSNP:rs202060209).
FT                                {ECO:0000269|PubMed:19630075}.
FT                                /FTId=VAR_069077.
FT   VARIANT      93     93       R -> W (in GLUT1DS2; dbSNP:rs267607061).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065207.
FT   VARIANT      95     95       S -> I (in GLUT1DS2; dbSNP:rs267607060).
FT                                {ECO:0000269|PubMed:20574033}.
FT                                /FTId=VAR_065208.
FT   VARIANT      96     96       M -> V (in GLUT1DS1; dbSNP:rs753161833).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065209.
FT   VARIANT     126    126       R -> C (in GLUT1DS1, GLUT1DS2 and DYT9;
FT                                reduced transporter activity;
FT                                dbSNP:rs80359818).
FT                                {ECO:0000269|PubMed:12325075,
FT                                ECO:0000269|PubMed:19798636,
FT                                ECO:0000269|PubMed:21832227}.
FT                                /FTId=VAR_054757.
FT   VARIANT     126    126       R -> H (in GLUT1DS1; significantly
FT                                decreases the transport of 3-O-methyl-D-
FT                                glucose and dehydroascorbic acid; 57% of
FT                                wild-type glucose uptake activity;
FT                                dbSNP:rs80359816).
FT                                {ECO:0000269|PubMed:11603379,
FT                                ECO:0000269|PubMed:12325075,
FT                                ECO:0000269|PubMed:15622525,
FT                                ECO:0000269|PubMed:20574033}.
FT                                /FTId=VAR_013183.
FT   VARIANT     126    126       R -> L (in GLUT1DS1; compound
FT                                heterozygote with V-256;
FT                                dbSNP:rs80359816).
FT                                {ECO:0000269|PubMed:10980529}.
FT                                /FTId=VAR_013184.
FT   VARIANT     130    130       G -> S (in GLUT1DS1; 75% of wild-type
FT                                glucose uptake activity;
FT                                dbSNP:rs80359819).
FT                                {ECO:0000269|PubMed:15622525,
FT                                ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_054758.
FT   VARIANT     146    146       E -> K (in GLUT1DS1; dbSNP:rs80359820).
FT                                {ECO:0000269|PubMed:10980529,
FT                                ECO:0000269|PubMed:12325075}.
FT                                /FTId=VAR_013284.
FT   VARIANT     149    149       P -> A (in EIG12; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23280796}.
FT                                /FTId=VAR_076229.
FT   VARIANT     153    153       R -> C (in GLUT1DS1; 44% of wild-type
FT                                glucose uptake activity).
FT                                {ECO:0000269|PubMed:12325075,
FT                                ECO:0000269|PubMed:15622525}.
FT                                /FTId=VAR_054759.
FT   VARIANT     153    153       R -> H (in GLUT1DS2; dbSNP:rs794727642).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065210.
FT   VARIANT     155    155       A -> V (in GLUT1DS1).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065211.
FT   VARIANT     165    165       V -> I (in GLUT1DS2).
FT                                {ECO:0000269|PubMed:20621801}.
FT                                /FTId=VAR_065212.
FT   VARIANT     169    169       Missing (in GLUT1DS1; 48% of wild-type
FT                                glucose uptake activity).
FT                                {ECO:0000269|PubMed:15622525}.
FT                                /FTId=VAR_054760.
FT   VARIANT     212    212       R -> C (in GLUT1DS1 and DYT9;
FT                                dbSNP:rs387907312).
FT                                {ECO:0000269|PubMed:20129935,
FT                                ECO:0000269|PubMed:21832227}.
FT                                /FTId=VAR_065213.
FT   VARIANT     212    212       R -> H (in GLUT1DS1).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065214.
FT   VARIANT     218    218       R -> S (in EIG12; decreased glucose
FT                                transport).
FT                                {ECO:0000269|PubMed:23280796}.
FT                                /FTId=VAR_076230.
FT   VARIANT     223    223       R -> P (in EIG12; mild phenotype; reduced
FT                                transporter activity; dbSNP:rs397514564).
FT                                {ECO:0000269|PubMed:19798636,
FT                                ECO:0000269|PubMed:20574033}.
FT                                /FTId=VAR_065215.
FT   VARIANT     223    223       R -> Q (in EIG12; unknown pathological
FT                                significance; no effect on glucose
FT                                transport; dbSNP:rs397514564).
FT                                {ECO:0000269|PubMed:23280796}.
FT                                /FTId=VAR_076231.
FT   VARIANT     223    223       R -> W (in GLUT1DS1; dbSNP:rs796053248).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065216.
FT   VARIANT     232    232       R -> C (in EIG12; the mutant protein is
FT                                expressed at the cell surface but has
FT                                mildly decreased glucose uptake (70%)
FT                                compared to wild-type;
FT                                dbSNP:rs387907313).
FT                                {ECO:0000269|PubMed:22282645}.
FT                                /FTId=VAR_069078.
FT   VARIANT     243    243       E -> V (in EIG12; decreased glucose
FT                                transport).
FT                                {ECO:0000269|PubMed:23280796}.
FT                                /FTId=VAR_076232.
FT   VARIANT     256    256       K -> E (in GLUT1DS1; compound
FT                                heterozygote with L-126;
FT                                dbSNP:rs121909738).
FT                                {ECO:0000269|PubMed:10980529}.
FT                                /FTId=VAR_013185.
FT   VARIANT     275    275       A -> T (in GLUT1DS2; the mutation
FT                                decreases glucose transport but does not
FT                                affect cation permeability;
FT                                dbSNP:rs121909740).
FT                                {ECO:0000269|PubMed:18451999}.
FT                                /FTId=VAR_054761.
FT   VARIANT     282    285       Missing (in GLUT1DS2; accompanied by
FT                                hemolytic anemia and altered erythrocyte
FT                                ion concentrations; the mutation
FT                                decreases glucose transport and causes a
FT                                cation leak that alteres intracellular
FT                                concentrations of sodium potassium and
FT                                calcium). {ECO:0000269|PubMed:18451999}.
FT                                /FTId=VAR_054762.
FT   VARIANT     286    286       G -> D (in SDCHCN; no effect on protein
FT                                abundance; no effect on localization to
FT                                the plasma membrane; loss of D-glucose
FT                                transporter activity; increased cation
FT                                leakage; dbSNP:rs864309514).
FT                                {ECO:0000269|PubMed:21791420,
FT                                ECO:0000269|PubMed:22492876}.
FT                                /FTId=VAR_076233.
FT   VARIANT     292    292       Y -> YY (in GLUT1DS1).
FT                                {ECO:0000269|PubMed:19901175}.
FT                                /FTId=VAR_069079.
FT   VARIANT     294    294       S -> P (in GLUT1DS2).
FT                                {ECO:0000269|PubMed:20830593}.
FT                                /FTId=VAR_065784.
FT   VARIANT     295    295       T -> M (in GLUT1DS1; 75% of wild-type
FT                                glucose uptake activity;
FT                                dbSNP:rs80359823).
FT                                {ECO:0000269|PubMed:15622525,
FT                                ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_054763.
FT   VARIANT     303    303       V -> L (found in a patient with GLUT1
FT                                deficiency syndrome).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065217.
FT   VARIANT     310    310       T -> I (in GLUT1DS1; dbSNP:rs80359824).
FT                                {ECO:0000269|PubMed:10227690}.
FT                                /FTId=VAR_013285.
FT   VARIANT     314    314       G -> S (in GLUT1DS2; the mutation
FT                                decreases glucose transport but does not
FT                                affect cation permeability;
FT                                dbSNP:rs121909739).
FT                                {ECO:0000269|PubMed:18451999,
FT                                ECO:0000269|PubMed:20574033}.
FT                                /FTId=VAR_054764.
FT   VARIANT     317    317       N -> T (in GLUT1DS2).
FT                                {ECO:0000269|PubMed:21204808}.
FT                                /FTId=VAR_065218.
FT   VARIANT     324    324       S -> L (in GLUT1DS2; mild phenotype;
FT                                reduced transporter activity;
FT                                dbSNP:rs796053253).
FT                                {ECO:0000269|PubMed:19798636,
FT                                ECO:0000269|PubMed:20574033}.
FT                                /FTId=VAR_065219.
FT   VARIANT     329    329       E -> Q (in GLUT1DS1; stabilizes the
FT                                inward-open conformation).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065220.
FT   VARIANT     333    333       R -> Q (in GLUT1DS1 and GLUT1DS2).
FT                                {ECO:0000269|PubMed:19630075,
FT                                ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065221.
FT   VARIANT     333    333       R -> W (in GLUT1DS1; 43% of wild-type
FT                                glucose uptake activity;
FT                                dbSNP:rs80359825).
FT                                {ECO:0000269|PubMed:10980529,
FT                                ECO:0000269|PubMed:12325075,
FT                                ECO:0000269|PubMed:15622525}.
FT                                /FTId=VAR_013286.
FT   VARIANT     382    382       G -> D (in GLUT1DS1).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065222.
FT   VARIANT     405    405       A -> D (in GLUT1DS1).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065223.
FT   VARIANT     411    411       N -> S (in EIG12; decreased glucose
FT                                transport; dbSNP:rs398123069).
FT                                {ECO:0000269|PubMed:23280796}.
FT                                /FTId=VAR_076234.
FT   VARIANT     435    435       Missing (in SDCHCN; no effect on protein
FT                                abundance; no effect on localization to
FT                                the plasma membrane; loss of D-glucose
FT                                transporter activity; increased cation
FT                                leakage). {ECO:0000269|PubMed:21791420,
FT                                ECO:0000269|PubMed:22492876}.
FT                                /FTId=VAR_076235.
FT   VARIANT     458    458       R -> W (in EIG12; decreased glucose
FT                                transport; dbSNP:rs13306758).
FT                                {ECO:0000269|PubMed:23280796}.
FT                                /FTId=VAR_076236.
FT   VARIANT     468    468       R -> W (in GLUT1DS1; dbSNP:rs267607059).
FT                                {ECO:0000269|PubMed:20221955}.
FT                                /FTId=VAR_069080.
FT   VARIANT     485    485       P -> L (in GLUT1DS1).
FT                                {ECO:0000269|PubMed:20129935}.
FT                                /FTId=VAR_065224.
FT   MUTAGEN      45     45       N->T: Loss of glycosylation site.
FT                                {ECO:0000269|PubMed:24847886}.
FT   MUTAGEN     192    192       I->C: Strongly decreases glucose
FT                                transport. {ECO:0000269|PubMed:18245775}.
FT   MUTAGEN     204    204       L->C: Abolishes glucose transport.
FT                                {ECO:0000269|PubMed:18245775}.
FT   MUTAGEN     205    205       P->C: Abolishes glucose transport.
FT                                {ECO:0000269|PubMed:18245775}.
FT   MUTAGEN     340    340       G->C: Strongly decreases glucose
FT                                transport. {ECO:0000269|PubMed:19449892}.
FT   CONFLICT     25     26       Missing (in Ref. 2; BAF85480).
FT                                {ECO:0000305}.
FT   CONFLICT     95     95       S -> L (in Ref. 2; BAF85480).
FT                                {ECO:0000305}.
FT   CONFLICT    152    152       L -> F (in Ref. 1; AAA52571).
FT                                {ECO:0000305}.
FT   HELIX        11     30       {ECO:0000244|PDB:5EQG}.
FT   HELIX        37     52       {ECO:0000244|PDB:5EQG}.
FT   HELIX        58     90       {ECO:0000244|PDB:5EQG}.
FT   HELIX        92     98       {ECO:0000244|PDB:5EQG}.
FT   HELIX       100    111       {ECO:0000244|PDB:5EQG}.
FT   TURN        112    117       {ECO:0000244|PDB:5EQG}.
FT   HELIX       119    145       {ECO:0000244|PDB:5EQG}.
FT   TURN        150    152       {ECO:0000244|PDB:5EQG}.
FT   HELIX       153    156       {ECO:0000244|PDB:5EQG}.
FT   HELIX       159    174       {ECO:0000244|PDB:5EQG}.
FT   TURN        177    180       {ECO:0000244|PDB:5EQG}.
FT   TURN        183    185       {ECO:0000244|PDB:5EQG}.
FT   HELIX       186    191       {ECO:0000244|PDB:5EQG}.
FT   HELIX       194    203       {ECO:0000244|PDB:5EQG}.
FT   HELIX       204    206       {ECO:0000244|PDB:5EQG}.
FT   HELIX       211    215       {ECO:0000244|PDB:5EQG}.
FT   TURN        216    218       {ECO:0000244|PDB:5EQG}.
FT   HELIX       221    232       {ECO:0000244|PDB:5EQG}.
FT   HELIX       238    253       {ECO:0000244|PDB:5EQG}.
FT   HELIX       259    264       {ECO:0000244|PDB:5EQG}.
FT   TURN        266    268       {ECO:0000244|PDB:5EQG}.
FT   HELIX       269    283       {ECO:0000244|PDB:5EQG}.
FT   TURN        284    286       {ECO:0000244|PDB:5EQG}.
FT   HELIX       288    301       {ECO:0000244|PDB:5EQG}.
FT   HELIX       306    328       {ECO:0000244|PDB:5EQG}.
FT   HELIX       333    356       {ECO:0000244|PDB:5EQG}.
FT   TURN        357    360       {ECO:0000244|PDB:5EQG}.
FT   HELIX       364    379       {ECO:0000244|PDB:5EQG}.
FT   TURN        380    385       {ECO:0000244|PDB:5EQG}.
FT   HELIX       386    394       {ECO:0000244|PDB:5EQG}.
FT   TURN        397    399       {ECO:0000244|PDB:5EQG}.
FT   HELIX       400    429       {ECO:0000244|PDB:5EQG}.
FT   HELIX       430    432       {ECO:0000244|PDB:5EQG}.
FT   HELIX       433    451       {ECO:0000244|PDB:5EQG}.
SQ   SEQUENCE   492 AA;  54084 MW;  E71E1C6BD1B00B1E CRC64;
     MEPSSKKLTG RLMLAVGGAV LGSLQFGYNT GVINAPQKVI EEFYNQTWVH RYGESILPTT
     LTTLWSLSVA IFSVGGMIGS FSVGLFVNRF GRRNSMLMMN LLAFVSAVLM GFSKLGKSFE
     MLILGRFIIG VYCGLTTGFV PMYVGEVSPT ALRGALGTLH QLGIVVGILI AQVFGLDSIM
     GNKDLWPLLL SIIFIPALLQ CIVLPFCPES PRFLLINRNE ENRAKSVLKK LRGTADVTHD
     LQEMKEESRQ MMREKKVTIL ELFRSPAYRQ PILIAVVLQL SQQLSGINAV FYYSTSIFEK
     AGVQQPVYAT IGSGIVNTAF TVVSLFVVER AGRRTLHLIG LAGMAGCAIL MTIALALLEQ
     LPWMSYLSIV AIFGFVAFFE VGPGPIPWFI VAELFSQGPR PAAIAVAGFS NWTSNFIVGM
     CFQYVEQLCG PYVFIIFTVL LVLFFIFTYF KVPETKGRTF DEIASGFRQG GASQSDKTPE
     ELFHPLGADS QV
//
